The current Ebola outbreak in the Democratic Republic of the Congo is driven by the Bundibugyo virus, a rare strain with no approved treatment or vaccine, and containment has been hampered by security issues, population displacement, and strikes by health workers over pay.

More than 50 health workers have died since the outbreak began, underscoring the deadly toll on frontline responders.

Efforts include the deployment of Ervebo doses from the global stock, with about 70,000 doses allocated to the DRC in August, alongside international support such as a $267 million contribution from the United States to fight Ebola.

The outbreak has surpassed 8,000 confirmed cases, reaching 8,067 cases and 3,901 deaths across 63 health zones in seven provinces, with a case fatality rate above 48% as of late September.

There are signs of improvement in regions like Ituri and Haut-Uele, yet the disease is spreading to new areas, expanding its geographic reach.

Overall, the outbreak has touched seven provinces with over 7,700 confirmed cases and nearly 3,760 deaths, while some areas report declines in new cases between late August and mid-September.

A Reuters interview with Dr. Kaseya on the sidelines of the UN General Assembly in New York highlights intensified international attention and pressure to control the outbreak.

Health authorities are identifying roughly 60 contacts per confirmed case, revealing the extensive transmission network and ongoing containment challenges.

Dr. Jean Kaseya of the Africa CDC says the outbreak remains entrenched in communities despite some progress, signaling a persistent shortfall in the response.

The World Health Organization warns that sustained challenges in timely case detection and access to adequate care keep the case-fatality rate high.

About 30,000 people have been identified as potential exposures, illustrating large gaps in reach and surveillance amid contact tracing efforts.

The Ervebo vaccine currently protects against the Zaire variant, while ongoing studies aim to assess its effectiveness against the Bundibugyo variant.